Radiation therapy for vulvar cancer: consensus guidelines of the GINECOR working group of the Spanish Society of Radiation Oncology. Part 1: clinical recommendations.

Data de publicació: 24/03/2023 Data Ahead of Print: 24/03/2023

Autors de IIS La Fe

Francisco Javier Celada Álvarez

Autor

Autors aliens a IIS La Fe

Cordoba Largo S
Rodriguez, Isabel Rodriguez
Rodriguez Villalba S
Najjari Jamal D
Anchuelo Latorre J
Garcia Cabezas S
de la Fuente Alonso C
Couselo Paniagua L
Martínez Montesinos I
Villafranca Iturre E
Belinchón Olmeda B
Farga Albiol D
Navarrete Solano PA
Sánchez Belda M
GINECOR (Spanish Gynaecological Tumors Group of SEOR)

Grups d'Investigació

Investigación Clínica y Traslacional en Cáncer

Leader

José Gómez Codina

Abstract

PURPOSE: The present consensus statement was developed by the GINECOR working group on behalf of the Spanish Society of Radiation Oncology (SEOR). Given the lack of prospective data on the management of vulvar carcinoma, this document provides an up-to-date review of radiotherapy treatment in vulvar cancer and a series of consensus-based recommendations from a group of experts. METHODS: A two-round, online modified Delphi study was conducted to reach consensus treatment recommendations in three clinical settings: 1) adjuvant treatment, 2) locally-advanced vulvar cancer (LAVC), and 3) recurrent disease. After the first round, we comprehensively reviewed the available medical literature from peer-reviewed journals to assess and define the evidence-based treatment options. In the second round, participants were asked to indicate their level of agreement with the preliminary recommendations according to the GRADE (Grade of Recommendation, Assessment, Development, and Evaluation) criteria, as follows: strongly agree; agree; neither agree nor disagree; disagree; strongly disagree. RESULTS: The main recommendations were as follows: 1) following surgical resection, adjuvant radiotherapy is recommended with the presence of adverse risk factors (primarily positive margins and lymph node involvement); 2) radiotherapy (with or without chemotherapy) should be considered in LAVC; and 3) in recurrent disease, radiotherapy should be individualised on a case-by-case basis. A high level of agreement over 80% was reached. CONCLUSIONS: In the absence of robust clinical data, these final recommendations may help to select the optimal radiotherapy approach for this relatively rare cancer.

Dades de la publicació

ISSN/ISSNe:: 1699-048X, 1699-3055
Tipus:: Article
Pàgines:: 2153-2168
DOI:: 10.1007/s12094-023-03095-8
PubMed:: 36961727
Factor d'Impacte:: 0,764 SCImago ℠
Quartil:: Q2 SCImago ℠

Documents

No hi ha documents

Mètriques

Filiacions

Cordoba Largo S:: Department of Radiation Oncology, Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain.
Rodriguez, Isabel Rodriguez:: Department of Radiation Oncology, La Paz University Hospital, Madrid, Spain
Rodriguez Villalba S:: Department of Radiation Oncology, Clinica Benidorm Hospital, Benidorm, Alicante, Spain
Najjari Jamal D:: Department of Radiation Oncology, Catalan Institut of Oncology, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain
Anchuelo Latorre J:: Department of Radiation Oncology, Marqués de Valdecilla University Hospital, Santander, Spain
Celada Álvarez F:: Department of Radiation Oncology, La Fe, University Hospital and Politécnico, Valencia, Spain
Garcia Cabezas S:: Department of Radiation Oncology, Reina Sofía, University Hospital, Córdoba, Spain
de la Fuente Alonso C:: Department of Radiation Oncology, Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain
Couselo Paniagua L:: Department of Radiation Oncology, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
Martínez Montesinos I:: Department of Radiation Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain
Villafranca Iturre E:: Department of Radiation Oncology, University Hospital of Navarra, Pamplona, Spain
Belinchón Olmeda B:: Department of Radiation Oncology, La Paz University Hospital, Madrid, Spain
Farga Albiol D:: Department of Radiation Oncology, La Fe, University Hospital and Politécnico, Valencia, Spain
Navarrete Solano PA:: Department of Radiation Oncology, Marqués de Valdecilla University Hospital, Santander, Spain
Sánchez Belda M:: Department of Radiation Oncology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain